Company: IXHL
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029414
Chunk: 20

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 20
---
 to our drug candidates; |

| ● | any inability to obtain adequate supply of our drug candidates or the inability to do so at acceptable prices; |

| ● | adverse regulatory authority decisions; |

| ● | introduction of new products, services or technologies by our competitors; |

| ● | failure to meet or exceed financial and development projections we may provide to the public; |

| ● | failure to meet or exceed the financial and development projections of the investment community; |

| ● | the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; |

| ● | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; |

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent 
 protection for our technologies;                                                                                                       |

| ● | additions or departures of key personnel; |

| ● | significant lawsuits, including patent or stockholder litigation; |

| ● | failure by securities or industry analysts to publish research or reports about our business, or issuance of any adverse or misleading 
 opinions by such analysts regarding our business or stock;                                                                             |

| ● | changes in the market valuations of similar companies; |

| ● | general market or macroeconomic conditions, such as inflation; |

| ● | fluctuations of exchange rates between the U.S. dollar and the Australian dollar; |

| ● | sales of our common stock by us or our stockholders in the future; |

| ● | the trading volume of our common stock; |

| ● | our ability to maintain the listing of our common stock on the Nasdaq Global Market; |

| ● | announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant 
 contracts, commercial relationships or capital commitments                                                                         |

| ● | the introduction of technological innovations or new therapies that compete with our potential drugs; |

| ● | changes in the structure of healthcare payment systems; |

| ● | the impact of political instability and military conflicts, such as the conflicts and recent events in Ukraine and the Middle East, 
 which has resulted in instability in the global financial markets and export controls; and                                          |

| ● | period-to-period fluctuations in our financial results. |

Moreover, the stock markets
in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies.
These broad market fluctuations may also adversely affect the trading price of our common stock. If the price of our common stock declines,
our ability to raise